The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, ...

The Japanese MHLW has granted approval for MSD’s KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve ...

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet ...

Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011. Read what makes AMGN stock is a worthy ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

The EMA CHMP has recommended approval of MSD’s KEYTRUDA for two gynaecological cancers: endometrial and cervical.

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in ...